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Abstract
Background: Although originally marketed as safe alternatives to the habit-forming benzodiazepines, growing numbers 
of zaleplon, zolpidem, and zopiclone (“Z-drugs”) clinical concerns relating to their potential of abuse, dependence, and 
withdrawal have been reported over time. We aimed here at assessing these issues analyzing datasets of adverse drug 
reactions provided by the European Medicines Agency through the EudraVigilance system.
Methods: Analyzing the adverse drug reactions databases of each Z-drug, descriptive analyses have been performed on cases 
and proportional reporting ratios (PRRs) computed.
Results: An overall number of 33 240 (e.g., 23 420 zolpidem; 9283 zopiclone; and 537 zaleplon) misuse-, abuse-, dependence-, and 
withdrawal-related adverse drug reactions, corresponding to some 6246 unique patients given Z-drugs, were here identified. Cases 
were studied and described, including demographic characteristics and clinical data such as concomitant drugs, doses, routes of 
administration, and outcomes of the reactions (being fatalities recorded). Considering PRR values and in comparison with zopiclone, 
zolpidem was more frequently involved in both misuse/abuse and withdrawal issues. Zolpidem and zopiclone presented with the 
same dependence risk, but zopiclone was most involved in overdose adverse drug reactions. Compared with zaleplon, zopiclone 
presented higher dependence and overdose-related issues but slightly lower misuse/abuse and withdrawal PRR values.
Conclusion: Current data may only represent a gross underestimate of the real prevalence of Z-drug misuse. Caution should 
be exercised when prescribing those molecules, especially for patients with psychiatric illnesses and/or history of drug abuse. 
We recommend the need to invest in proactive pharmacovigilance activities to better and promptly detect, understand, and 
prevent any possible misuse potential of prescribed medications.
Keywords: adverse drug reactions, Z-drugs, zolpidem, zaleplon, zopiclone, EMA
Introduction
Although sharing with benzodiazepines a similar mechanism 
of action, the non-benzodiazepine hypnotics zaleplon, zolpi-
dem, and zopiclone (“Z-drugs”) appeared on the market as safe 
substitutes for benzodiazepines, purportedly having both a 
reduced abuse potential and propensity to tolerance and with-
drawal due to improved pharmacokinetics (Gunja, 2013). Despite 
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such expectations, many cases of misuse, abuse, dependence, 
and death involving Z-drugs have been reported over the last 
decade or so (Atkin et al., 2018).
Clinical Pharmacological Issues
Z-drugs are GABA-A receptor modulators chemically unrelated 
to benzodiazepines approved for the short-term management 
of insomnia disorders (NICE, 2004) due to their hypnotic effects 
by reducing sleep latency and improving sleep quality (Nutt and 
Stahl, 2010). Like benzodiazepines, Z-drugs are agonists of the 
GABA receptor complex and therefore enhance GABA-mediated 
neuronal inhibition. However, their binding selectivity and 
pharmacokinetic profiles have been reported to minimize the 
possibility of side-effects similar to those produced by benzo-
diazepines, for example, next day sedation, dependence, and 
withdrawal (NICE, 2004).
Among Z-drugs, zopiclone was the first compound devel-
oped, binding with high affinity and functional potency the ben-
zodiazepine receptor complex. With an absorption time of about 
2 hours and an elimination half-life of 4 to 5 hours, its clinical 
use is in the 3.75- to 7.5-mg dosage range (EMC, 2017). Zolpidem 
is an imidazopyridine with an oral bioavailability of 70% and an 
elimination half-life of 2.5 hours (NICE, 2004; Nutt and Stahl, 
2010). It is normally indicated at 10-mg dosages (Victorri-Vigneau 
et al., 2007). Zaleplon is a rapidly absorbed pyrazolopyrimidine 
with an elimination half-life of 1 hour (NICE, 2004). Zaleplon use 
at a 5- to 20-mg dosage is currently indicated for use only in 
patients with initial insomnia, and an extended-release formu-
lation is in development (Ebert et  al., 2006). Z-drug treatment 
should usually vary from a few days to 2 weeks with a maximum 
of 4 weeks, including tapering-off where appropriate.
Misuse, Abuse, Dependence, and Withdrawal Issues
Despite the reported lack of tolerance and dependence (Lader, 
1992; Voderholzer et  al., 2001; Zammit, 2009), the occurrence 
of both rebound insomnia (Lader, 1992; Ebert et  al., 2006) and 
withdrawal symptoms after a therapeutic dosage abrupt dis-
continuation of Z-drugs has been described, and especially so 
in alcohol-dependent and drug-abusing patients (Ayonrinde 
and Sampson, 1998; Hajak, 1999; Hajak et al., 2003; Johansson 
et  al., 2003; Ebert et  al., 2006; Zammit, 2009; Morinan and 
Keaney, 2010). Furthermore, a range of case series and postmar-
keting surveillance studies have given rise to growing clinical 
concerns among clinicians (Victorri-Vigneau et  al., 2014), sug-
gesting that the prevalence of Z-drug misuse issues could have 
been underestimated compared with benzodiazepines (Zammit, 
2009). Z-drug withdrawal symptoms, typically associated with 
the abrupt cessation of long-term, high-dosage intake, may 
include insomnia, anxiety, euphoria irritability, tremor, inner 
restlessness, speech difficulties, abdominal pain, hypertension, 
tonic-clonic seizures, and confusion/disorientation/delirium 
(Aranko et  al., 1991; Wong et  al., 2005; Flynn and Cox, 2006). 
The use of either idiosyncratic routes of administration (e.g., 
injecting) or the intake of high dosages may well increase the 
risk of Z-drug abuse (Victorri-Vigneau et al., 2007). Drug misus-
ers may be attracted by Z-drugs because they are not typically 
monitored during drug treatment programs (Sikdar and Ruben, 
1996; Rooney and O’Conner, 1998; Gunja, 2013; Ott et al., 2017; 
Schifano et al., 2018).
Z-Drug Current Regulation, Near Misses, and 
Fatalities
According to the World Health Organization, the occurrence of 
zolpidem abuse and dependence would be similar to that of 
benzodiazepines and, different from zopiclone and zaleplon, in 
2001 this molecule was placed in the same schedule of benzo-
diazepines (UNODC, 2001). Conversely, in 2013 the UK’s Advisory 
Council on the Misuse of Drugs concluded that zaleplon and 
zopiclone should be controlled in the same manner as zolpi-
dem. Overall, zaleplon tends to be reported as the least misused, 
and zopiclone and zolpidem are both identified as the most mis-
used (ACMD, 2013).
To assess the Z-drug misuse-, abuse-, dependence-, and 
withdrawal-related issues, our study aimed at analyzing the 
related European Medicines Agency (EMA) EudraVigilance (EV) 
databases, collecting the voluntary reports of suspected ADRs 
for all medicinal products authorized in the European Economic 
Area (EEA).
Methods
The European pharmacovigilance system and its functions 
of detection, assessment, understanding, and prevention of 
adverse drug reactions (ADRs) or any other drug-related problem 
have been improved in parallel with the 2012 pharmacovigilance 
legislation (EMA, 2016a; Sessa et al., 2018). The EMA is respon-
sible for the safety monitoring of medicines operating through 
EV, a system managing and analyzing information on suspected 
ADRs to medicines that have been authorized in the EEA (EMA, 
2016a), although reports are received from non-EEA countries as 
well (for a better understanding of the EMA organization of data 
collection, please refer to the supplementary material).
To assess Z-drug misuse issues, a formal request was sent to 
EMA for all misuse, abuse, dependence, and withdrawal Z-drug-
related data. The Individual Case Safety Reports were identified 
considering the Preferred Terms (PTs) mentioned. The request 
included the following PTs: “drug abuse,” “intentional product 
misuse,” “drug dependence,” and “withdrawal syndrome” or all 
the PTs included in the broad Standardised MedDRA Queries 
“Drug abuse, dependence and withdrawal” (MedDRA, 2018). The 
level 2A EV frequency table and line listing of the requested 
ADRs were here retrieved. Level 2A access meant that cases 
were provided with general information (e.g., sender, type of 
report, reporter qualification), some anonymized patient infor-
mation, reaction (event) information with its outcome, and 
Significance Statement
Although originally marketed as safe alternatives to the habit-forming benzodiazepines, growing concerns about zaleplon, zolpi-
dem, and zopiclone (“Z-drugs”) abuse, dependence, and withdrawal issues have been reported over the the last decade. The 
analysis of Z-drug related misuse, abuse, dependence, and withdrawal cases collected by the European Medicines Agency (EMA) 
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drug-related information (e.g., start date, duration, dose, phar-
macological form, route of administration) (see also EMA, 2018). 
In the EV database, each individual patient had a code (EV local 
number) for unequivocal identification. ADR numbers differed 
from those referring to single patients, since different report-
ers/senders could have independently flagged the same ADR to 
EMA. Conversely, several ADRs (involving various organ classes, 
hence identified with specific PTs) relating to the searched ADR 
(e.g., abuse, misuse, dependence, and withdrawal) could have 
been reported as well for the same patient (HMA EMA, 2017). 
The zolpidem, zopiclone, and zaleplon data analysis referred to 
a range of parameters, including sociodemographic character-
istics (age and sex), source/reporter country (EEA or non-EEA) 
and reporter qualification (i.e., pharmacist, physician), ADR 
outcome (fatal, recovered, resolved), drug dosages, and possi-
ble concomitant drug(s). The analysis included cases of abuse/
misuse/dependence and withdrawal ADRs, focusing on fatali-
ties as well. Suicides were here reported as “suicide attempt,” 
“suicidal behaviour,” and “intentional self-injury”; conversely, 
“suicidal ideation,” and “overdose” (including intentional) were 
not included (MedDRA, 2018). The ADRs considered here were, 
per se, voluntary and unsolicited communications reported by 
both Regulatory Authorities of the EU Member States where 
the reaction occurred, and/or by the Marketing Authorisation 
Holders for those ADRs occurring outside the EEA. Within the 
Standardised MedDRA Queries drug abuse, dependence, and 
withdrawal section, the following adverse reactions were identi-
fied: dependence, drug abuser, drug diversion, drug use disorder, 
drug withdrawal convulsions, drug withdrawal headache, drug 
withdrawal syndrome, intentional overdose, intentional prod-
uct misuse, intentional product use issue, overdose, prescrip-
tion drug use without prescription, product use in unapproved 
indication, product use issue, substance use disorder, substance 
abuser, and withdrawal syndrome. “Misuse” was here meant to 
be the “intentional use for a therapeutic purpose by a patient or 
consumer of a product, over-the-counter or prescription, other 
than as prescribed or not in accordance with the authorised 
product information.” Conversely, “abuse” was defined here as 
the “intentional, non-therapeutic use by a patient or consumer 
of a product, over-the-counter or prescription, for a perceived 
reward or desired non-therapeutic effect including, but not 
limited to, getting high (euphoria).” The term “addiction,” typi-
cally replaced by “dependence,” is the “overwhelming desire by 
a patient or consumer to take a drug for non-therapeutic pur-
poses together with inability to control or stop its use despite 
harmful consequences.” Finally, “withdrawal” referred here to 
“a substance-specific syndrome which follows cessation or 
reduction in the intake of a psychoactive substance previously 
regularly used” (MedDRA, 2018). Those ADRs that were listed as 
“suspect drug,” meaning that the reporter suspected this drug 
and not the concomitant medicine(s) to have caused the index 
ADR (EMA, 2016a), were here included.
The proportional reporting ratio (PRR) approach, defined as 
“the ratio between the frequency with which a specific adverse 
event is reported for the drug of interest (relative to all adverse 
events reported for the drug) and the frequency with which the 
same adverse event is reported for the drug(s) in the compari-
son group (relative to all adverse events for drugs in the com-
parison group),” was here considered (EMA EV-Ewg, 2006). A PRR 
>1 suggests that the adverse event is more commonly reported 
for individuals taking the drug of interest relative to the com-
parison drug(s), whereas if the PRR value is <1, there is a dispro-
portion of reporting in the sense that the specific event is less 
frequently reported in association with the suspect drug than 
with the others. The PRR confidence intervals were here com-
puted as well, indicating with PRR− and PRR+, respectively, the 
lower and upper bounds of the 95% confidence interval (EMA 
EV-Ewg, 2006; for a better understanding of the PRR calculation, 
please refer to the supplementary material).
Ethics
Because of EMA protection of privacy and integrity of individu-
als, data relating to patients affected were fully and completely 
deidentified/anonymized; therefore, it was not possible at all to 
derive from such data the names of the individuals affected by 
the ADR, not even their country or town. Hence, per definition, 
the need to obtain their informed consent was here not appli-
cable. Moreover, certain data elements (e.g., names/identifiers 
of individuals involved; country-specific information, nationally 
authorized products, etc.) were not disclosed (EMA, 2016b).
The study has been ethically approved by the University of 
Hertfordshire Ethics Committee, with reference number LMS/
PGR/UH/03234 (March 5, 2018).
Results
Zaleplon ADRs
Overall, the number of the EMA 2003 to 2017 zaleplon ADRs col-
lected by was 4270 (Table 1). Of the total number of ADRs, those 
relating to misuse, abuse, dependence, and withdrawal issues 
and judged by the reporter as “suspect” were 537 (12.58%), with 
“intentional overdose” being the most represented (51.9%). Most 
ADRs were reported by physicians from non-EEA countries 
(53.2%), while pharmaceutical companies were the most typical 
(58.6%) reporting agencies. Typically, these ADRs involved adult 
(18–64 years old) females. A lone Z-drug ingestion was reported 
in 33/112 (29.4%) of zaleplon, while a concomitant use of pre-
scription drugs mostly involved antidepressants (19.8%), benzo-
diazepines (17.8%), and ethanol/other Z-drugs (13.9%) has been 
described. A  nasal atypical intake modality was reported in 7 
zaleplon cases. No information of dosage was here provided.
Finally, a range of suicide-related (“suicide attempt” and 
“suicidal ideation”) ADRs were reported (13.6% and 5.21%, 
respectively).
Zolpidem ADRs
Of the total number of zolpidem ADRs (206 315), those relating 
to misuse-abuse-dependence-withdrawal issues and judged 
by the reporter as “suspect” were 23 420 (11.35%) (Table 1). Most 
ADRs were reported by physicians from non-EEA countries 
(49.7%), pharmaceutical companies having been the most typical 
(41.3%) reporting agencies. “Drug use disorder” (40.0%), “overdose” 
(23.7%), and “intentional overdose” (16.7%) were the most repre-
sented ADRs. Typically, these ADRs involved adult (18–64  years 
old) females. A lone Z-drug ingestion was reported in 1856/4374 
(42.4%) zolpidem cases, while a concomitant use of prescription 
drugs was reported, mostly involving antidepressants (26.6%), 
benzodiazepines (19.0%), and opiates/opioids (14.2%). Moreover, 
a range of recreational drugs was identified, specifically alcohol 
(174 cases), cocaine (30 cases), amphetamines (21 cases), and can-
nabis (13 cases). Atypical intravenous (22 cases), nasal (5 cases), 
and sublingual (1 case) intake modalities were here reported for 
zolpidem. Dosages were higher than 20 mg in 7371 ADRs, in 6234 
of these cases, the dosage was above 100 mg, and in 20 ADRs (7 
cases) it was in excess of 2000  mg. Finally, a range of suicidal 
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behavior-related ADRs was reported for zolpidem, including 
“intentional self-injury” (102/23  420: 0.5%), “suicidal behavior” 
(44/23 420: 0.2%), and “suicide attempt” (3101/23 420: 13.2%). The 
rates of ADRs with a fatal outcome were higher for zolpidem 
(20.3%) compared with both zopiclone (9.33%) and zaleplon (1.1%).
Zopiclone ADRs
As for zaleplon and zolpidem, most zopiclone-related ADRs 
were reported by physicians from non-EEA countries (45.8%), 
with pharmaceutical companies having been the most typi-
cal (51.4%) reporting agencies. Of the total number of ADRs 
(65  140), those relating to misuse-abuse-dependence-with-
drawal issues and judged by the reporter as “suspect” were 9283 
(14.25%) (Table 1), with the most represented ADRs including: 
“intentional overdose” (29.9%), “overdose” (23.1%), and “drug 
use disorder” (23.1%). Typically, these ADRs involved adult (18–
64 years old) females. A lone zopiclone ingestion was reported 
in 416/1760 (23.6%) cases; as for zaleplon and zolpidem, a con-
comitant use of prescription drugs was reported, mostly involv-
ing benzodiazepines in 891/4374 (20.4%) cases, antidepressants 
in 658/4374 (15.0%) cases, antipsychotics in 475/4374 (10.9%) 
cases, and opiates/opioids in 131/4374 cases (2.99%). Moreover, 
a range of recreational drugs was identified (e.g., cannabis in 12 
cases, cocaine in 6 cases, methamphetamines in 1 case), and 
intravenous and subcutaneous intake modalities were reported 
as well. Finally, as for zolpidem, a range of suicidal behavior-
related ADRs was reported, including “intentional self-injury” 
(111/9283:1.2%), “suicidal behavior” (43/9283: 0.5%), and “suicide 
attempt” (2526/9283: 27.2%). When dosages were reported, levels 
in excess of 15  mg were described in 577 (360 individuals) of 
zopiclone cases, including 205 ADRs (120 cases) where the dos-
age ingested was in the 450- to 2250-mg range.
Analysis of the PRR Values
Considering the PRR values (Tables 2 and 3), compared with zop-
iclone, zolpidem was more involved in both misuse/abuse and 
withdrawal issues, while zopiclone was more involved in over-
dose ADRs. Conversely, zolpidem and zopiclone presented with 
the same dependence risk. If compared with zaleplon, zopiclone 
and zolpidem presented higher dependence and withdrawal, 
but slightly lower misuse/abuse and withdrawal, PRR values. 
Lower and upper bounds of the PRR confidence interval are 
reported in Table 3.
Discussion
To the best of our understanding, this paper is the first to provide 
uniquely systematic data in terms of identification and analysis 
of zolpidem, zopiclone, and zaleplon misuse, abuse, dependence, 
and withdrawal issues. The present data were extracted from a 
high-quality, large-scale, pharmacovigilance database such as 
the EMA’s EV. Together with the World Health Organization’s 
Drug Monitoring Program, the EV database is considered a 
worldwide reference standard (Schifano and Chiappini, 2018). 
Most literature papers, so far, were based on small case series/
single case studies (Aranko et al., 1991; Sikdar and Ruben, 1996; 
Rooney and O’Conner, 1998; Wong et al., 2005; Flynn and Cox, 
2006; Chiaro et al., 2018). Conversely, current findings referred 
to overall much larger (e.g., 33 240 ADRs; corresponding to some 
6246 unique cases) numbers of patients presenting with Z-drug 
misuse issues. Indeed, current data may represent only a gross 
underestimate of the Z-drug misuse issues’ real prevalence. In 
fact, reports were here submitted spontaneously, and levels of 
misperception that these drugs are safe, which could prevent 
professionals from reporting, may still be identified (Medsafe, 
1998). The analyses of the EV databases confirmed the diversion 
potential and the possibility of abuse, misuse, dependence, and 
withdrawal issues related to all Z-drugs (zaleplon, zopiclone, 
and zolpidem), albeit some differences have emerged within 
this group. Compared with zaleplon, the misuse/abuse issues 
seemed here to be lower for zopiclone and zolpidem. Conversely, 
compared with zopiclone, zolpidem emerged as being more fre-
quently related to misuse or abuse and withdrawal reports; if 
Table 1. Number of EMA Database Z-Drug Misuse-, Abuse-, Dependence-, and Withdrawal-Related ADRs (2003–2017)
 Zaleplon Zopiclone Zolpidem
Total no. ADRs 4270 65 140 206 315
Suspect abuse-, 
misuse-, 
dependence-, or 
withdrawal-related 
ADRs
537 (12.58%) (IC 95%: 11.60–13.61%) 9283 (14.25%) (IC 95%: 13.98–14.52%) 23 420 (11.35%) (IC 95%: 
11.21–11.49%)
No. of unique 
patients
112 1760 4374
Gender most 
typically 
represented
F (F/M ratio: 3.9) F (F/M ratio: 1.09) F (F/M ratio: 1.6)
Age range (y) 
most typically 
represented
18–64 (39%) 18–64 (68%) 18–64 (65.7%)
ADRs most typically 
represented
Intentional overdose (51.9%), overdose 
(14.1%), drug use disorder (11.4%)
Intentional overdose (29.9%), overdose 
(23.1%), drug use disorder (23.1%)
Drug use disorder (40.0%), 
overdose (23.7%), intentional 
overdose (16.7%)
Concomitant drugs 
most typically 
represented
Antidepressants in 20/101 (19.8%) 
cases, benzodiazepines in 18/101 
(17.8%) cases, ethanol/other Z drugs in 
14/101 (13.9%) cases
Benzodiazepines in 891/4374 (20.4%) 
cases, antidepressants in 658/4374 
(15.0%) cases, antipsychotics in 
475/4374 (10.9%) cases
Antidepressants in 
468/1760 (26.6%) cases, 
benzodiazepines in 334/1760 
(19.0%) cases, opiates/opioids 
in 250/1760 (14.2%) cases
Abbreviations: ADR, adverse drug reaction; CI, confidence interval; EMA, European Medicines Agency.
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compared with zaleplon, zolpidem was more frequently related 
to dependence and overdose reports. Among Z-drugs, zolpidem 
was the most frequently reported in the EV dataset, being asso-
ciated with intravenous administration, very high dosage con-
sumption, and concomitant use of recreational drugs. These data 
are consistent with previous suggestions (Griffiths and Johnson, 
2005; Rousselet et  al., 2017) and recent reports based on both 
zolpidem-related falsified prescription rates in France (Jouanjus 
et al., 2018) and clinical dependence issue data from an Indian 
tertiary care center (Shukla et al., 2017). Overall, zaleplon ADRs 
were numerically lower than zopiclone- and zolpidem-related 
ADRs and less frequently associated with both idiosyncratic/
atypical ways of administration and concomitant recreational 
drug intake. Hence, one could tentatively identify in zaleplon the 
relatively (Desousa, 2009; Paparrigopulos et al., 2008) “most safe” 
Z-drug. A full comparison among Z-drugs should, however, con-
sider as well the precise worldwide prescription figures, which 
could serve as a proper denominator. Indeed, within the Z-drug 
group, one could argue that zaleplon may present with the low-
est availability levels due to its higher purchase costs (NICE, 
2004). Regarding zopiclone use, Jaffe et  al. (2004) assessed its 
use among 297 drug addicts who had been consecutively admit-
ted to addiction treatment centers in the United Kingdom. It 
emerged that more than half had used zopiclone, which ranked 
fourth after diazepam, temazepam, and nitrazepam. About 80% 
of zopiclone users had obtained the drug through a prescrip-
tion, but 42% reported having purchased it on the streets (Jaffe 
et al., 2004). Analyzing the misuse patterns of benzodiazepine 
Table 2. Z-Drug Misuse-, Abuse-, Dependence-, Withdrawal-, and Overdose-Related ADRs; PRR Computation
Zaleplon ADRs No of reactions ADRs Proportion of zaleplon ADRs
Drug abuser (A1) + drug diversion (A2) + drug use disorder (A3) + intentional product use 
issue (A4) + intentional product misuse (A5) + prescription drug used without  
prescription (A6) + product use in unapproved indication (A7) + product use issue 
(A8) + substance abuser (A9) + substance use disorder (A10)
367 0.089
Dependence (A11) 5 0.001
Withdrawal syndrome (A12) + drug withdrawal syndrome (A13) + drug withdrawal 
headache (A14) + drug withdrawal (A15)
89 0.023
Intentional overdose (A16) + overdose (A17) 76 0.019
Other adverse events (B) 3733 0.868
Total 4270 1.000
Zopiclone ADRs No of reactions ADRs Proportion of zopiclone 
ADRs
Drug abuser (C1) + drug diversion (C2) + drug use disorder (C3) + intentional  
product use issue (C4) + intentional product misuse (C5) + prescription drug used 
without prescription (C6) + product use in unapproved indication (C7) + product use  
issue (C8) + substance abuser (C9) + substance use disorder (C10)
2507 0.043
Dependence (C11) 138 0.002
Withdrawal syndrome (C12) + drug withdrawal syndrome (C13) + drug withdrawal 
headache (C14) + drug withdrawal (C15)
718 0.013
Intentional overdose (C16) + overdose (C17) 5920 0.096
Other adverse events (D) 55 857 0.846
Total 65 140 1.000
Zolpidem ADRs No of reactions  
ADRs
Proportion of  
zolpidem ADRs
Drug abuser (E1) + drug diversion (E2) + drug use disorder (E2) + intentional  
product use issue (E4) + intentional product misuse (E5) + prescription drug used 
without prescription (E6) + product use in unapproved indication (E7) + product use  
issue (E8) + substance abuser (E9) + substance use disorder (E10)
9744 0.050
Dependence (E11) 423 0.002
Withdrawal syndrome (E12) + drug withdrawal syndrome (E13) + drug withdrawal 
headache (E14) + drug withdrawal (E15)
2433 0.018
Intentional overdose (E16) + overdose (E17) 10 820 0.056
Other adverse events (F) 182 895 0.874
Total 206 315 1.000
Abbreviations: ADR, adverse drug reaction; PRR, proportional reporting ratio.
Table 3. Z-Drug PRR Values
 
PRR Zolpidem vs Zaleplon  
(PRR− and PRR+)
PRR Zopiclone vs Zaleplon  
(PRR− and PRR+)
PRR Zolpidem vs Zopiclone 
(PRR− and PRR+)
Misuse/abuse ADRs 0.57 (0.55–0.59) 0.48 (0.43–0.53) 1.16 (1.11–1.21)
Dependence ADRs 2.00 (0.82–4.8) 2.00 (0.81–4.80) 1.00
Withdrawal ADRs 0.79 (0.76–0.81) 0.56 (0.29–1.06) 1.38 (1.27–1.49)
Overdose ADRs 2.90 (2.31–3.60) 5.00 (4.00–6.2) 0.58 (0.56–0.60)
Abbreviations: ADR, adverse drug reaction; PRR, proportional reporting ratio.
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and Z-drug users, Kapil et al. reported that 29.6% had ever mis-
used them, with 40.5% of individuals misusing at least 2 of these 
medications. Diazepam (53.4%) and zopiclone (24.1%) were the 
most frequently reported medications, with decreasing num-
bers of individuals misusing lorazepam (22.4%), alprazolam 
(17.2%), zaleplon (11.2%), nitrazepam (10.3%), phenazepam 
(7.8%), and zolpidem (5.2%). Moreover, iUsing data from a health 
insurance reimbursement database, which collects information 
from 77% of the French population, Ponté et al. (2018) assessed 
the extent and risk of opioid analgesic abuse related to benzo-
diazepines and hypnotics; they considered both the molecules’ 
Doctor Shopping Quantity (intended to assess the extent of 
abuse) and the Doctor Shopping Index (DSI; intended to iden-
tify a signal of abuse). Interestingly, they found that the Doctor 
Shopping Quantity of anxiolytics and hypnotics (influenced by 
their large availability levels) was 10 times higher than that of 
opioids. Conversely, the DSI of opioids (2.79%) was higher than 
that of both hypnotics (2.06%) and anxiolytics (1.81%). Among 
benzodiazepines, flunitrazepam and zolpidem presented with 
the highest DSI values (13.2% and 2.2%, respectively) (Ponté 
et  al., 2018). Overall, higher levels of physical and compulsive 
signs of dependence with zolpidem, rather than with zopiclone 
(Griffiths and Johnson, 2005; Rousselet et al., 2017; Ponté et al., 
2018), have been described.
Current Z-drug data are consistent with the new trends in 
prescription drug misuse (Throckmorton et  al., 2018), which 
is at times occurring within the context of the rising levels of 
novel psychoactive substances misuse (Schifano et al., 2018). It 
is, however, concerning that a range of other prescription and 
recreational psychotropics were here identified in combina-
tion with Z-drugs, including antidepressants, benzodiazepines, 
antipsychotics, other Z-drugs, opiates/opioids, alcohol, can-
nabis, cocaine, methamphetamine, and ketamine. The present 
data may support previous hypotheses, for example, that there 
may be 2 subsets of individuals misusing Z-drugs; the first group 
may include patients with psychiatric comorbidities (Zammit, 
2009; Lin et  al., 2017), who were originally started with these 
molecules for insomnia but who developed tolerance and with-
drawal phenomena, therefore requiring increasing dosages 
overtime (Griffiths and Johnson, 2005); and the second popula-
tion may include young people, who are ingesting large Z-drug 
dosages in combination with other recreational compounds 
and through idiosyncratic intake modalities (Sikdar and Ruben, 
1996; Ayonrinde and Sampson, 1998; Rooney and O’Conner, 
1998; Hajak, 1999; Johansson et  al., 2003), which can increase 
the drug bioavailability levels (Victorri-Vigneau et al., 2007) and 
hence facilitate achieving better euphoria.
Fatalities were here reported for all Z-drugs, although this 
typically occurred mostly with zolpidem and zopiclone, both 
typically ingested in a poly-drug misuse scenario, thus con-
firming previous reports (Garnier et al., 1994; Casula et al., 2013; 
Gunja, 2013). The comparatively low levels of zaleplon toxicity/
fatalities here identified could, however, be associated with the 
molecule’s ultra-short half-life and rapid antemortem metabo-
lism, which can affect its detection (Gunja, 2013). Mortality from 
Z-drugs may be similar to that of benzodiazepines (Garnier 
et al., 1994; Reith et al., 2003). A UK study on zopiclone-related 
deaths (Buckley and McManus, 2004) found that the zopiclone 
fatal toxicity index was similar to that of zolpidem but lower 
compared with flurazepam, flunitrazepam, temazepam, tria-
zolam, and nitrazepam. It is of interest to note that a number of 
suicidal behavior-related ADRs (e.g., suicide attempts, suicidal 
ideation) were here identified, and especially so for both zolpi-
dem and zopiclone. This confirms previous findings, suggest-
ing increasing levels of suicidal ideation, suicide attempts, and 
suicide risk in patients administered with Z-drugs (Brower et al., 
2011; MCCall et al., 2017).
Limitations
The number of any given compound-related ADRs may not 
reflect the full extent of the molecule’s potential of misuse. In 
fact, levels of reporting, which is voluntary in nature, depend 
on the index molecule clinician’s awareness of safety concerns, 
its market availability levels, and extent of use. Furthermore, a 
Z-drug illicit market exists (Kapil et al., 2014), further compli-
cating the computation of a reliable, Z-drug availability level 
denominator. The ADRs reports presented with missing data, 
such as the dosages ingested and the background diagnosis. 
Based on the current reporting rules in the EEA, report dupli-
cations were possible as well, that is, the same ADR could be 
reported by different healthcare professionals. To mitigate this 
issue, however, the number of individual cases was unequivo-
cally identified through a code number. Finally, suspected 
ADRs do not conclusively prove causality between a specific 
drug and a given ADR; the ADR may be a symptom of another 
illness, or it could be associated with another medical prod-
uct taken by the patient at the same time or caused by their 
interaction.
Conclusions
In being perceived as more effective and tolerable hypnot-
ics, the level of Z-drug availability has increased over time 
in parallel with a decrease in benzodiazepine prescriptions 
(Siriwardena et  al., 2006; ACMD, 2013). However, both previ-
ous number of anecdotal reports and current data may well 
suggest that the misuse, abuse, dependence, and withdrawal 
issues may be associated with the use of all Z-drugs, although 
zaleplon may present comparatively lower levels of risk. 
Present data may further support the need to encourage care-
ful prescribing, in line with the UK government’s initiative to 
review the evidence for dependence on, and withdrawal from, 
prescribed medicines (Pollmann et al., 2015; Kuntz et al., 2017; 
Gov.uk, 2018). Special caution is here suggested in prescribing 
Z-drugs to vulnerable clients, for example, inmates, those with 
psychiatric comorbidities, and recreational drug misusers. To 
manage clinical Z-drug dependence cases, the use of benzodi-
azepines (e.g., diazepam or clonazepam), gabapentinoids, tra-
zodone, and quetiapine has been suggested (Mariani and Levin, 
2007; Pottie et al., 2018).
Voluntary reporting systems should be improved, with new 
tools/approaches hopefully to be made available. To assess the 
abuse potential of centrally active drugs, a range of both pre-
marketing evaluation and proactive postmarketing surveillance 
activities should be strongly encouraged. A proactive pharma-
covigilance may help monitor and anticipate changes in drug 
abuse, using elements of clinical, epidemiological, basic science, 
and social science expertise to increase clinicians’ awareness of 
drug safety issues (Throckmorton et al., 2018).
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